BioMarin to acquire Alesta Therapeutics in a to $ 490 million deal
LONDON: BioMarin Pharmaceutical Inc. has agreed to acquire Alesta Therapeutics, a clinical-stage biotechnology company, in a deal that could be worth up to $490 million, the companies announced Wednesday. The acquisition gives BioMarin control of ALE1, Alesta’s lead experimental drug candidate for hypophosphatasia, a…